European Patent Office

T 2200/17 (TENOFOVIR PRODRUG / GILEAD SCIENCES) of 08.03.2021

European Case Law Identifier
ECLI:EP:BA:2021:T220017.20210308
Date of decision
8 March 2021
Case number
T 2200/17
Petition for review of
-
Application number
01961695.2
Language of proceedings
English
Distribution
No distribution (D)
OJ versions
No OJ links found
Other decisions for this case
-
Abstracts for this decision
-
Application title
PRODRUGS OF PHOSPHONATE NUCLEOTIDE ANALOGUES AND METHODS FOR SELECTING AND MAKING SAME
Applicant name
GILEAD SCIENCES, INC.
Opponent name
Teva Pharmaceutical Industries Ltd
Swindell & Pearson Limited
STRAWMAN LIMITED
HEXAL PHARMA AG
Board
3.3.02
Headnote
-
Relevant legal provisions
European Patent Convention Art 54European Patent Convention Art 56European Patent Convention Art 87Rules of procedure of the Boards of Appeal Art 12(1)Rules of procedure of the Boards of Appeal Art 12(2)Rules of procedure of the Boards of Appeal Art 13(2)
Keywords
Priority - validity of priority date (yes)
Novelty - (yes)
Inventive step - (yes)
Unsubstantiated objection - admitted (no)
Submissions after summons - admitted (no)
Catchword
-
Citing cases
G 0002/21T 0356/22

Order

For these reasons it is decided that:

The appeals are dismissed.